GlassScriptPhysician profile
Grant William Jirka
NPI 1326667346
$8,221.35
in general payments reported to CMS, 2019-2025
45 companies · $3,573 in 2025
The $3,573 reported for 2025 was more than what 77% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,633 · 2024: $3,015 · 2025: $3,573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,498 · Education: $548 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,498.41 |
| Education | $547.94 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $728.81 | 2023-2025 | |
| Janssen Biotech, INC. | $723.02 | 2023-2025 | Darzalex, Tecvayli, Talvey |
| Genzyme Corporation | $585.55 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $561.46 | 2023-2025 | Ultomiris |
| Gilead Sciences, INC. | $390.50 | 2024-2025 | Trodelvy |
| Karyopharm Therapeutics INC. | $348.65 | 2023-2025 | Xpovio |
| Merck Sharp & Dohme LLC | $347.68 | 2023-2025 | Keytruda, Keytruda Qlex, Dificid |
| Celgene Corporation | $338.26 | 2023-2025 | Reblozyl |
| Emd Serono, INC. | $327.49 | 2023-2025 | Bavencio |
| Jazz Pharmaceuticals INC. | $318.07 | 2023-2025 | |
| Blueprint Medicines Corporation | $253.85 | 2023-2025 | Ayvakit |
| Incyte Corporation | $250.16 | 2023-2025 | Monjuvi, Jakafi, Pemazyre |
| Astrazeneca Pharmaceuticals LP | $217.35 | 2023-2025 | Calquence, Enhertu, Lynparza |
| Aadi Bioscience, INC. | $208.18 | 2024 | Fyarro |
| Daiichi Sankyo INC. | $203.05 | 2023-2025 | Enhertu, Vanflyta |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $182.38 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $180.26 | 2024-2025 | Reblozyl, Opdualag |
| Agios Pharmaceuticals, INC. | $174.49 | 2023-2025 | Pyrukynd |
| Ipsen Biopharmaceuticals, INC | $135.88 | 2023-2024 | Somatuline Depot, Onivyde |
| Sobi, INC | $124.03 | 2025 | |
| Lilly USA, LLC | $123.03 | 2023 | |
| Kite Pharma, INC. | $119.37 | 2025 | |
| Astellas Pharma US INC | $115.06 | 2023 | Xospata |
| Genentech USA, INC. | $113.69 | 2024-2025 | Tecentriq, Polivy, Phesgo |
| Adc Therapeutics America, INC. | $106.17 | 2023-2024 | |
| Seagen INC. | $99.99 | 2025 | |
| Servier Pharmaceuticals LLC | $98.17 | 2024-2025 | |
| Stemline Therapeutics INC. | $87.74 | 2025 | Orserdu, Elzonris |
| Puma Biotechnology, INC. | $86.43 | 2023-2024 | Nerlynx |
| Beone Medicines USA, INC. | $68.27 | 2025 | Brukinsa, Tevimbra |
| Syndax Pharmaceuticals, INC. | $64.80 | 2025 | |
| Dendreon Pharmaceuticals LLC | $64.28 | 2025 | Provenge |
| Rigel Pharmaceuticals, INC. | $60.96 | 2024-2025 | Rezlidhia, Tavalisse, Gavreto |
| Takeda Pharmaceuticals U.S.A., INC. | $56.93 | 2024-2025 | Livtencity, Ninlaro |
| Exelixis INC. | $55.57 | 2024-2025 | Cabometyx |
| Sumitomo Pharma America, INC. | $51.23 | 2025 | Orgovyx |
| Alnylam Pharmaceuticals INC. | $46.64 | 2024-2025 | Givlaari |
| Coherus Oncology, INC. | $43.80 | 2024 | |
| Geron Corporation | $34.87 | 2025 | Rytelo |
| Kyowa Kirin, INC. | $29.06 | 2024 | Poteligeo |
| Eisai INC. | $24.20 | 2024 | |
| Deciphera Pharmaceuticals INC. | $22.26 | 2025 | Tgct, Qinlock |
| Immunocore Limited | $17.18 | 2024 | Kimmtrak |
| Pfizer INC. | $16.62 | 2025 | |
| Btg International INC. | $15.91 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grant Jirka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.